Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 20, Issue 2, 2018, Pages 463-467

  Aggarwal, Naresh ^a   Singla, Anuj ^a   Mathieu, Chantal ^b   Montanya, Eduard ^c   Pfeiffer, Andreas F H ^d   Johnsson, Eva ^e   Zhao, June ^f   Iqbal, Nayyar ^f   Bailey, Clifford ^g  

^a AAA Clinical Research   (Canada)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e ASTRAZENECA R AND D   (Sweden)

^f ASTRAZENECA   (United Kingdom)

^g ASTON UNIVERSITY   (United Kingdom)

Author keywords

glycated haemoglobin; metformin extended release; once daily dosing; randomized clinical trial; type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BEDTIME DOSAGE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED DRUG RELEASE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMEDIATE DRUG RELEASE; INFORMED CONSENT; MAJOR CLINICAL STUDY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VOMITING; ADMINISTRATION AND DOSAGE; ANALYSIS; BLOOD; BLOOD GLUCOSE MONITORING; CHEMICALLY INDUCED; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIABETIC DIET; DOSE RESPONSE; DRUG MONITORING; EXERCISE; FEMALE; HYPERGLYCEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; SINGLE BLIND PROCEDURE;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; EXERCISE; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 85030631078     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13104     Document Type: Article

References (15)

1. US Food and Drugs Administration. Metformin hydrochloride tablets. http://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf. Accessed February 6, 2017.
2. US Food and Drug Administration. Drugs@FDA: FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021202. Accessed January 19, 2017.
3. European Medicines Agency. Annex I. List of nationally authorised medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Metformin_31/WC500201027.pdf. Accessed January 19, 2017.
4. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–579.
5. American Diabetes Association. Standards of medical care in diabetes - 2017: 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40:S64–S74.
6. Food and Drug Administration. New drug application. Bristol-Myers Squibb: NDA 20-357/S-031 and NDA 21-202/S-016. Glucophage® (metformin hydrochloride tablets) and Glucophage® XR (metformin hydrochloride extended-release tablets). http://packageinserts.bms.com/pi/pi_glucophage.pdf. Accessed December 19, 2016.
7. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44:721–729.
8. DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541–549.
9. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose–response relationship and safety of once-daily extended-release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7:28–39.
10. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11:338–342.
11. Gao H, Xiao W, Wang C, et al. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study. Int J Clin Pract. 2008;62:695–700.
12. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29:759–764.
13. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16.
14. Tsiatis AA, Davidian M, Zhang M, Lu X. Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med. 2008;27:4658–4677.
15. Zhang M, Tsiatis AA, Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics. 2008;64:707–715.